Insulet (NSDQ:PODD) said today that its Omnipod insulin management system is available in Europe for use with Novo Nordisk‘s (NYSE:NVO) Fiasp fast-acting insulin aspart.
Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet.
Get the full story at our sister site, Drug Delivery Business News.
The post Europe OKs Novo Nordisk’s Fiasp for Insulet’s Omnipod appeared first on MassDevice.
from MassDevice https://ift.tt/2y3jNWm
Cap comentari:
Publica un comentari a l'entrada